Hypothesis

Hormetic stressors do not merely "turn on" repair pathways; they create a temporary NAD⁺ dip that acts as a molecular switch. This dip transiently activates SIRT1 and AMPK, which then promote PINK1 stabilization and Nrf2‑ARE signaling to launch mitophagy. If the NAD⁺ depletion persists, PARP overconsumption overwhelms salvage pathways, shifting the balance toward apoptosis. Thus, the same NAD⁺‑dependent machinery can drive either survival or death depending on the duration and amplitude of the NAD⁺ fluctuation.

Mechanistic Rationale

• Baseline NAD⁺ levels support housekeeping sirtuin activity but are insufficient to sustain high‑flux mitophagy under aging‑related damage [2].
• A sharp ROS burst (e.g., from exercise, intermittent fasting, or low‑dose Urolithin A) rapidly oxidizes NADH, lowering the NAD⁺/NADH ratio and activating NAD⁺‑sensing enzymes: SIRT1 deacetylates PINK1/FOXO3, AMPK phosphorylates ULK1, and Nrf2 is released from KEAP1 [3][4].
• These kinases increase mitophagic flux and antioxidant transcription, clearing damaged mitochondria before they amplify ROS.
• If the stressor is prolonged or too intense, NAD⁺ consumption by PARP1 (activated by DNA damage) and CD38 outpaces NAD⁺ salvage (via NAMPT), collapsing the NAD⁺ pool. Low NAD⁺ then fails to sustain SIRT1/AMPK activity, while excess PARP‑mediated ADP‑ribosylation triggers AIF release and caspase‑independent apoptosis [1][6].

Testable Predictions

1. Transient hormetic pulses will produce a biphasic NAD⁺ trace: a rapid ~20‑30 % drop within 5 min, followed by return to baseline within 30‑60 min, coinciding with peak mitophagy (measured by mt‑Keima).
2. Sustained stressors (e.g., continuous high‑dose paraquat or chronic caloric restriction) will cause a progressive NAD⁺ decline (>50 % over several hours) and correlate with increased PARP‑1 autophosphorylation and apoptotic markers (cleaved caspase‑3, TUNEL).
3. Pharmacological NAD⁺ boosting (NMN or NR) during a hormetic pulse will blunt the NAD⁺ dip, attenuate SIRT1/AMPK activation, and reduce mitophagy without affecting baseline ROS.
4. Conversely, PARP inhibition (olaparib) during prolonged stress will preserve NAD⁺, shift the outcome from apoptosis to survival, and rescue mitophagy flux.

Experimental Approach

• Use live‑cell imaging with a NAD⁺‑specific biosensor (SoNar or Peredox) alongside mt‑Keima mitophagy reporter in human fibroblasts or C. elegans intestine.
• Apply defined hormetic stimuli: intermittent hypoxia, 2‑hour fasting, or 10 µM Urolithin A for 30 min vs. continuous exposure.
• Quantify NAD⁺/NADH ratios, SIRT1 activity (acetyl‑p53 levels), AMPK phosphorylation (Thr172), PARP‑1 autophosphorylation, and apoptotic readouts.
• Manipulate NAD⁺ metabolism with NMN, FK866 (NAMPT inhibitor), or PARP inhibitors, and assess whether the predicted shifts in cell fate occur.

Falsifiability

If hormetic interventions extend lifespan without producing a measurable, transient NAD⁺ dip, or if NAD⁺ supplementation does not diminish the mitophagic response to hormesis, the hypothesis would be falsified. Likewise, if blocking PARP fails to convert chronic stress outcomes from apoptosis to survival despite NAD⁺ preservation, the NAD⁺‑gate model would need revision.

By positioning NAD⁺ dynamics as the decisive factor that translates a threat signal into a binary survival/death decision, this hypothesis reframes hormesis not as a vague stress‑response but as a metabolically gated switch—offering a precise, quantifiable target for interventions that aim to harness the benefits of transient threat without tipping into damage.